Beranda › Kanker (semua jenis) › Michigan › Detroit
Uji klinis Kanker (semua jenis) di Detroit, MI
29 studi untuk Kanker (semua jenis) mencari peserta di lokasi sekitar Detroit (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Menerima pesertaFase 3
- Barbara Ann Karmanos Cancer Center, Detroit
- Henry Ford Cancer Institute-Henry Ford Hospital, Detroit
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Menerima pesertaFase 3
- Karmanos Cancer Center ( Site 0108), Detroit
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Menerima pesertaFase 2
- Henry Ford Health Saint John Hospital, Detroit
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Menerima pesertaFase 2/3
- Karmanos Cancer Center Wayne State University, Detroit
Connect for Cancer Prevention Study (Connect)
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Henry Ford Health Systems, Detroit
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Menerima pesertaFase 1/2
- GSK Investigational Site, Detroit
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Menerima pesertaFase 1
- Henry Ford Cancer Institute, Detroit
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Menerima pesertaFase 1/2
- Henry Ford Hospital, Detroit
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Menerima pesertaStudi observasional
- Karmanos Cancer Institute, Detroit
Project: Every Child for Younger Patients With Cancer
Menerima pesertaStudi observasional
- Children's Hospital of Michigan, Detroit
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Karmanos Cancer Institute, Detroit
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Menerima pesertaFase 3
- Henry Ford Health Saint John Hospital, Detroit
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Menerima pesertaFase 1/2
- Henry Ford Cancer Institute, Detroit
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Menerima pesertaFase 1
- Henry Ford Hospital, Detroit
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Menerima pesertaFase 1
- Henry Ford Health System, Detroit
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Henry Ford Hospital, Detroit
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Menerima pesertaFase 2
- Karmanos Cancer Center (Wayne State University), Detroit
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Menerima pesertaFase 1/2
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
Menerima pesertaFase 1
- GSK Investigational Site, Detroit
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
Menerima pesertaFase 1
- GSK Investigational Site, Detroit
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
Menerima pesertaFase 1/2
- Karmanos Cancer Institute, Detroit
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Menerima pesertaFase 1
- Henry Ford Cancer Institute, Detroit
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Menerima pesertaFase 1/2
- Henry Ford Health, Detroit
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
Menerima pesertaFase 1
- Karmanos Cancer Institute, Detroit
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
Menerima peserta
- Karmanos Cancer Institute, Detroit
A Beta-only IL-2 ImmunoTherapY Study
Menerima pesertaFase 1/2
- Karmanos Cancer Institute, Detroit
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Henry Ford Cancer Institute, Detroit
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Menerima pesertaFase 1/2
- Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center, Detroit
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
Menerima pesertaStudi observasional
- Henry Ford Health System, Detroit
Uji klinis Kanker (semua jenis) di kota lain
- Houston, TX121 studi
- New York City, NY109 studi
- Boston, MA85 studi
- Los Angeles, CA74 studi
- Nashville, TN65 studi
- Philadelphia, PA59 studi
- Washington, DC58 studi
- Durham, NC58 studi
- Chicago, IL51 studi
- Atlanta, GA49 studi
- Seattle, WA49 studi
- Arlington, VA48 studi
Studi lain di Detroit
- Kanker Paru Non-Sel Kecil44 studi
- Kanker Payudara33 studi
- Kanker Kolorektal26 studi
- Kanker Ovarium26 studi
- Kanker Metastatik24 studi
- Kanker Prostat22 studi
- Kanker Endometrium21 studi
- Kanker Paru20 studi
- Mieloma Multipel19 studi
- Kanker Lambung16 studi
- Karsinoma Sel Skuamosa Kepala dan Leher15 studi
- Leukemia Mieloid Akut14 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.